Reverse of the Differential Uptake Intensity of Tc-99m MIBI and Tc-99m V-DMSA By Multiple Myeloma Lesions in Response to Therapy

Athanasoulis, Theodoros; Koutsikos, John; Moulopoulos, Lia A.; Tsiouris, Spyridon; Dimopoulos, Meletios A.; Zerva, Cherry

doi:10.1097/01.rlu.0000079428.43330.b3

Cited by 10 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies speculated on the possible prognostic impact of 99mTc‐MIBI scintigraphy for MM patients (Pace et al , 2001, 2005a,b, 2006; Alexandrakis et al , 2002, 2003; Athanasoulis et al , 2003). Alexandrakis et al (2002) first investigated the 99mTc‐MIBI potential predictive value in patients with MM.…”

Section: Discussionmentioning

confidence: 99%

Technetium‐99m sestamibi scintigraphy is sensitive and specific for the staging and the follow‐up of patients with multiple myeloma: a multicentre study on 397 scans

et al. 2007

View full text Add to dashboard Cite

SummaryWe evaluated the additional benefit of Technetium 99 -sestamibi (99mTc-MIBI) scanning in comparison with standard X-ray techniques for multiple myeloma patients either at diagnosis or during follow-up. Between February 2001 and January 2005, 397 whole body scans were acquired. On 229 scans performed at diagnosis, 146 (64%) were positive and 81 cases have discordant X-ray results. The sensitivity of 99mTc-MIBI and X-ray were 77% and 45% respectively. As a result of 99mTc-MIBI, 40% of asymptomatic myeloma patients were up-staged. The positivity of 99mTc-MIBI correlated significantly with all of the most relevant clinical and biological parameters. Multivariate analysis selected only high reactive C protein (P ¼ 0AE0005), bone marrow infiltration (P ¼ 0AE02) and bone pain (P ¼ 0AE002) as factors affecting 99mTc-MIBI pattern. In 22 patients with solitary myeloma, 99mTc-MIBI was positive in 86% of cases and detected more disease sites than X-ray. Among 168 scans performed during follow-up, 99mTc-MIBI presented high specificity in patients showing a complete response (CR; 86%), and correlated with myeloma activity and with response to therapy. At multivariate analysis, a positive pattern correlated with bone marrow infiltration (P ¼ 0AE002) and disease status other than CR (P ¼ 0AE03). We conclude that 99mTc-MIBI scanning is an additional diagnostic tool with a high specificity for the staging and the follow-up of multiple myeloma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Technetium‐99m sestamibi scintigraphy is sensitive and specific for the staging and the follow‐up of patients with multiple myeloma: a multicentre study on 397 scans

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Moreover, V DMSA could be useful as a marker for bone metastasis [77,78] compared with FLT which presents intense accumulation in bone marrow.…”

Section: Phosphate Transport: Technetium 99m-pentavalent Dimercaptosumentioning

confidence: 98%

“…In this study, V DMSA appeared to be an easy and repeatable test to assess the viability of pituitary adenomas and to monitor the response to radiotherapy in this tumor type. However, some authors have shown that V DMSA uptake is dependent on necrosis, and demonstrated that increased accumulation of this tracer in multiple myeloma lesions after high-dose chemotherapy could be considered to be a sign of effectively treated lesions and not a sign of deterioration [77].…”

Section: Phosphate Transport: Technetium 99m-pentavalent Dimercaptosumentioning

confidence: 99%

Spectrum of Radiopharmaceuticals in Nuclear Oncology

Denoyer¹,

Perek²,

Jeune³

et al. 2006

CCDT

View full text Add to dashboard Cite

A major field of interest in nuclear medicine is in vivo tumor characterization and measurement of biological processes at cellular and molecular levels by means of positron emission tomography (PET) or single photon emission computed tomography (SPECT). Functional imaging with radiopharmaceuticals represents a useful noninvasive tool to evaluate the biological status of the tumor and its progression. The properties of radiopharmaceuticals are exploited for initial staging of cancer, assessment of recurrent or residual disease and, more recently, considerable progress has been made in the field of the evaluation of tumor response to treatment. PET and SPECT can both detect changes in tumor activity caused by therapy or disease progression before any detectable change in tumor volume. Measurement of tumor response to therapy using PET and SPECT is the subject of intense investigations because it may result in individualization of treatment and may have a prognostic value for long-term outcome. This review focuses on the various methods used to monitor anticancer therapy with a variety of clinically approved or investigational tracers. We summarize the mechanisms of radiopharmaceutical uptake based on certain physiological activities affected by treatment: proliferation, apoptosis, hypoxia, angiogenesis and multidrug resistance (MDR).

show abstract

“…54 Several studies have shown accumulation of 99m Tc-pentavalent dimercaptosuccinic acid ( 99m Tc-V-DMSA) in malignant tumors, 57,58 as well as in patients with myeloma. 59,60 Koutsikos et al evaluated the combined uptake of 99m Tc-V-DMSA and 99m Tc-MIBI to assess effectiveness after chemotherapy in patients with myeloma. As expected, 99m Tc-MIBI uptake in lesions was eliminated by high-dose chemotherapy, whereas 99m Tc-V-DMSA uptake was observed in lesions that initially had high 99m Tc-MIBI accumulation.…”

Section: Radionuclide Imagingmentioning

confidence: 99%